First report of Candidozyma auris in Vietnam

Early diagnosis and treatment of Candidozyma auris improve survival. At Cho Ray Hospital, the organism was successfully identified using Vitek 2 and Vitek MS systems. However, antifungal susceptibility testing remains challenging due to the lack of Clinical and Laboratory Standards Institute (CLSI) standards. The Microbiology Department follows provisional United States Centers for Disease Control and Prevention (U.S. CDC) guidelines and uses the broth microdilution method with the Sensititre YeastOne panel for testing. Candidozyma auris showed susceptibility rates of 81.6% to caspofungin, 94.7% to fluconazole, and 71.1% to amphotericin B. No isolates were resistant to all three antifungal classes, while 7.9% were resistant to two classes and 36.8% to one. Susceptibility patterns of 38 isolates were evaluated using both Sensititre YeastOne (microdilution with color) and Etest (agar diffusion), following CDC guidelines, to support method selection based on lab resources.